Orphan Drug Exclusivity Keeps Biosimilars Off the Market ...
文章推薦指數： 80 %
Orphan Drug Exclusivity Keeps Biosimilars Off the Market, Study Says ... Investigators found that manufacturers appear to be exploiting orphan ... BusinessPracticeSeeAll>BusinessDevelopmentLegalPolicyPracticeRegulatoryAboutContactAdvisoryBoardDoNotSellMyInformationTerms&
延伸文章資訊
- 1ORPHAN DRUGS IN THE UNITED STATES: - National ...
development in the rare disease space by offering grants, tax credits for clinical trial costs, w...
- 2Orphan drug - Wikipedia
An orphan drug is a pharmaceutical agent developed to treat medical conditions which, because the...
- 3The Enduring Role of Orphan Drug Exclusivity for Biologics ...
Orphan Drugs receive a 7-year period of exclusivity from product approval - effective on the date...
- 4Designating an Orphan Product: Drugs and Biological ...
The Orphan Drug Act (ODA) provides for granting special status to a drug or biological product (“...
- 5Newly passed House bill could close orphan drug loophole ...
The FDA can grant seven years of market exclusivity to a drug if it's intended to treat a conditi...
